Wednesday, February 19, 2020

Dr. Ge Li Awarded “CEO of the Year” at CPhI Worldwide 2019

November 11, 2019: WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, announced today that its...

WuXi AppTec Reports Third-Quarter 2019 Results

(SHANGHAI, October 30, 2019) — WuXi AppTec Co., Ltd. (stock code: 603259.SH/2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical,...

WuXi STA’s Jinshan Facility Passes EMA Inspection

SHANGHAI, October 28, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announced today that its Jinshan manufacturing facility in Shanghai, China has successfully passed an inspection...

WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space...

SHANGHAI, CHINA; CAMBRIDGE, MASSACHUSETTS, USA; SANKT AUGUSTIN, GERMANY Oct 10, 2019 - WuXi AppTec Research Service Division and BioSolveIT today launched a new virtual chemical space called GalaXi®. Largely built from WuXi...

WuXi AppTec Reports First Half 2019 Interim Results

Revenue Accelerated 33.7% Year-Over-Year to RMB 5,894 Million Gross Profit Up 30.0% Year-Over-Year to RMB 2,284 million1  Adjusted Non-IFRS Net...

Subscribe to our Newsletter

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

Amicus Therapeutics: A Patient-First Approach to Treating Rare Diseases

Rare diseases have long posed a dual challenge. First, since there are relatively few patients by definition, they are not the highest priority for...